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Background: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) is increasing due to fundamental
changes in oncogenesis related to effects of the human papilomavirus (HPV). Virally-mediated tumours behave and
respond to treatment differently than their classic, carcinogenically-mediated counterparts despite similar stage and
grade of disease. This difference in behaviour has lead to investigation of etiologies of OPSCC at the molecular
level.
Molecular biomarkers offer potential insight into the behaviour of OPSCC. Identifying a subset of patients that are
more likely to have recurrence and distant metastasis is valuable for prognostication and treatment planning. There
is limited information regarding the profiles of these biomarkers in locoregional and distant metastases in OPSCC.
Objective: This study was designed to identify biomarker profiles predictive of locoregional and distant metastases
and recurrence in OPSCC.
Methods: Cross-sectional study of a prospectively-collected oropharyngeal tumour database was undertaken. All
patients with OPSCC presenting to the University of Alberta Hospital from 2002-2009 were included in the study.
Data collection from the Alberta Cancer Registry, including demographics, nodal status, distant metastases,
treatment, recurrence, and survival, was undertaken. Tissue micro-arrays (TMAs) were constructed for each tumour
specimen using triplicate cores (0.6mm) of formalin-fixed, paraffin-embedded (FFPE) pre-treatment tumour tissue.
TMAs were processed using immunohistochemistry for p16, EGFR, Ki67, p53, and Bcl-XL. Positivity for each
biomarker was determined using quantified AQUAnalysis ® scores on histoplots. Multivariate statistics were utilized
to assess the relationship between each biomarker and locoregional and distant metastases, as well as
recurrence-free survival (RFS).
Results: High expression of p16 (p=0.000) and Bcl-XL (p=0.039) independently demonstrated a significant
association with nodal disease at presentation. Kaplan-Meier analysis demonstrated improved RFS in patients with
high p16 and decreased RFS in patients with high p53 expression. Cox regression analysis supported p16 as an
independent prognosticator for improved RFS. p53 demonstrated an association with recurrence, but when
compared to p16 status, nodal status, and staging, was not an independent predictor of recurrence.
Conclusions: Biomarker profiling using p16, Bcl-xL, and p53 may be useful in prognostication and treatment
planning in patients with OPSCC.
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Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common malignancy worldwide, with oro-
pharyngeal squamous cell carcinoma (OPSCC) accounting
for approximately half of these cancers. The major etio-
logical factors associated with OPSCC are alcohol con-
sumption, tobacco use, and human papillomavirus (HPV)
infection. Carcinogenic and virally-mediated events in-
duce numerous molecular and genetic alterations, causing
abnormal molecular processes that eventually manifest
as malignancies. The present treatment protocols for
OPSCC are based on the anatomic extent of the disease
(TNM staging) and do not take into account the ongoing
biologic and molecular processes. Treatment protocols in-
volving surgery, radiation, and/or chemotherapy are ag-
gressive and may lead to significant toxicity, especially
when used as combined modalities.
Molecular biomarkers are known to be useful in pre-
dicting survival outcomes for OPSCC patients. Onco-
genic HPV infection is associated with upregulation of
p16, a protein now widely utilized as a surrogate marker
of HPV-positive disease [1,2]. Many authors have shown
that HPV-positive oropharyngeal cancers are associated
with significantly improved survival. Other molecular
biomarkers including epidermal growth factor receptor
(EGFR), B-cell lymphoma extra large (Bcl-xL), p53, and
Ki67, have been shown to have prognostic significancei
[3]. High EGFR expression has been correlated with
poorer survival, while low levels of the anti-apoptotic
protein, Bcl-xL, have been shown to be associated with
improved response to radiation [4]. A recent study has
suggested that elevated Ki67 levels may be associated
with improved response to radiotherapy [5]. Despite
the available data, there has been limited investigation
regarding the role of different biomarker profiles in
locoregional and distant metastasis of OPSCC. Identify-
ing a subset of patients that are more likely to have
recurrence and distant metastases is valuable when
counselling patients about treatment options and prog-
nosis, and making treatment decisions.
The purpose of this study was to identify specific bio-
marker profiles predictive of nodal disease at presentation,
the development of distant metastases, and potential for
recurrence in patients with OPSCC.
Methods
Approval for the study was obtained from the University
of Alberta Health Research Ethics Board (Pro00016426).
Study population
The study population was comprised of 237 histologically-
confirmed OPSCC patients diagnosed between 2002–2009
at the University of Alberta, Edmonton, Canada. All
patients were treated with primary surgery, and furtheradjuvant treatment was determined by the final patho-
logic results. Demographic and clinicopathologic pa-
tient characteristics were collected from the Alberta
Cancer Registry (ACR).
Tissue microarray (TMA) construction
Tissue microarrays (TMAs) were constructed from
pre-treatment tumour tissue. Patients with small pre-
treatment biopsy specimens that would require sacrifice
of the entire block were not included (accounting for ap-
proximately 20% of patients who were treated with non-
surgical protocols). Formalin-fixed, paraffin-embedded
(FFPE) tumour samples were retrieved for TMA construc-
tion. Hematoxylin and eosin-stained (H&E) slides were
obtained from surgical specimens and reviewed by a Head
and Neck pathologist to confirm the diagnosis of squa-
mous cell carcinoma (SCC). Each TMA was assembled
from duplicate or triplicate 0.6 mm cores randomly sam-
pled from the tumour-containing area of each FFPE block.
Five samples of normal tonsil tissue from patients with no
history of HPV infection or OPSCC were included in the
TMAs as reference samples to ascertain normal bio-
marker expression levels.
Quantitative fluorescent immunochemistry
Each TMA was deparaffinized in xylene, rinsed in ethanol,
and rehydrated. Heat-induced epitope retrieval for Ki67
was achieved by heating slides to 121 degrees Celcius in a
citrate-based Target Retrieval Solution (pH 6.0) (Dako) for
6 minutes in a decloaking chamber. For Bcl-XL, the slides
were bathed in an EDTA-containing Target Retrieval
Solution (pH 9.0) (Dako) for 3 minutes, and each slide
was stained for Bcl-XL using rabbit monoclonal anti-Bcl-
XL (1:500 dilution, Cell Signalling). Rabbit Envision+ was
used with tyramide-Cy3 (Perkin-Elmer) for Ki67, or
tyramide-Cy5 (Perkin-Elmer) for Bcl-XL, to determine the
expression of each biomarker in the TMA cores. A similar
isolation technique was used for EGFR in accordance
with previous reporting [6]. TMA slides were stained for
rabbit monoclonal anti-EGFR antibody (1:1000 dilution,
Epitomics) for 60 minutes. Rabbit Envision+ kit (DAKO)
was used in conjunction with Tyramide-Cy5 (Perkin-
Elmer) to visualize EGFR expression. p53 was isolated as
previously published using mouse monoclonal anti-p53
(DAKO) [7]. p16 was isolated in a similar manner as has
been previously reported [8]. p16 was also isolated using a
commercially-available p16 antibody (Clone Jc8; Novus
Biologicals, Littleton, CO). The intensity of p16 staining
was scored using a 4-point (0–3) semi-quantitative scale
(0=negative; 1=weak, <5%; 2=focally strong, 5-80%; 3= dif-
fusely strong, >80%). Tissue from HPV-infected cervical
intraepithelial neoplasia was used as the p16-positive con-
trol. The highest score amongst the 3 cores was used for
analysis, and the tumour was graded as p16-negative
Table 1 Chi-squared analysis of p16, Ki67, EGFR, p53, and
Bcl-xL with nodal disease at presentation and
development of distant metastases in OPSCC patients
treated with all modalities from 2002–2009




x2 p-value x2 p-value
p16 12.480 0.000** 0.225 0.748
Ki67 0.410 0.737 1.830 0.189
EGFR 0.870 0.427 0.793 0.508
p53 3.407 0.092 0.548 0.561
Bcl-xL 4.915 0.039** 0.113 0.852
**Denotes statistical significance.
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pancytokeratin (PCK) antibody and an Alexa488 conju-
gated anti-guinea pig secondary antibody were used to
identify the entire epithelial tumour compartment. Slides
were mounted using Prolong Gold Anti-fade with DAPI
(Invitrogen).
Each TMA was scanned by HistoRx™ PM-2000 and ana-
lyzed using AQUAnalysis® software (version 2.2.1.7). The
PCK-positive region was denoted as the tumour com-
partment, the DAPI-positive region was denoted as the
tumour nuclear compartment, and the Ki67 compartment
area was defined as the Ki67 positive area inside the
tumour nuclear compartment. Areas with less than 20%
tumour tissue were determined to be insufficient for ana-
lysis and were excluded from the analysis (approximately
20% of non-surgical specimens). The AQUAnalysis® soft-
ware compared each tumour core to normal oropharyn-
geal squamous tissue to establish a baseline expression
value. AQUA scores representing the exposure time-
adjusted pixel intensity density of biomarker proteins
within the tumour compartment of each core were calcu-
lated and a quantified value of the expression of each bio-
marker was obtained for further analysis.
Statistical analysis
All statistical analyses were performed using SPSS
(Version 21.0). The expression value for each bio-
marker was qualified as positive based on current litera-
ture standards or, when there were no standards, values
above the median for the cohort were qualified as positive.
For p16, cores that expressed greater than 80% positivity
on the histoplot generated by the AQUAnalysis® software
were considered positive, as is consistent with current lit-
erature standards [9]. For EGFR, values that were more
than one standard deviation below the mean were consid-
ered low. For p53, Bcl-XL, and Ki67, values that were
above the median value calculated for the entire cohort of
226 specimens were deemed positive. A Chi-squared ana-
lysis was used to evaluate the association between the
positivity of each biomarker and nodal disease at presen-
tation, as well as the development of distant metastatic
disease. Chi-squared analysis was also utilized to deter-
mine associations and clinical co-existence of biomarker
expression. Kaplan-Meier analysis was used to assess
5-year recurrence-free survival (RFS) for each biomarker
profile, and a Cox regression analysis was utilized to
evaluate the prognostic value of each biomarker compared
to the other biomarkers, and to known prognosticators of
recurrence (stage, nodal status).
Results
Cohort characteristics
226 specimens were available for analysis and had ad-
equate tumour tissue for generation of Histoplot analysiswith AQUAnalysis® software. The average age of the pa-
tients was 58.1 years. The study population with adequate
tumor specimens consisted of 177 males and 49 females.
Nodal disease at presentation existed in 84% of the study
population. 88.5% of patients had advanced-stage disease
(Stage 3 or 4). All patients were treated curatively with
multiple modalities including primary surgical or radi-
ation treatment regimens. Median follow-up time was ap-
proximately 2.88 years. The recurrence-free survival (RFS)
for the study population was 74.8%.Biomarker expression
Chi-squared analysis demonstrating the relationship be-
tween biomarker expression and nodal disease at presen-
tation as well as the development of distant metastases
is demonstrated in Table 1. Kaplan-Meier analysis and
relevant survival curves are demonstrated in Table 2 and
Figures 1 and 2. Cox regression analysis comparing the
effect of each biomarker on recurrence-free survival
(RFS) both with (Table 3) and without known prognosti-
cators of recurrence (Table 4) is also demonstrated.p16 expression
p16 positivity was confirmed in 112 patients (48.7%). High
p16 expression was correlated with nodal disease at pres-
entation (p=0.000, Table 1), and this was substantiated by
further univariate and multivariate analyses (p=0.001,
p=0.049). Combined biomarker analysis revealed a sig-
nificant inverse association between expression of p16
and p53 (p=0.003). Kaplan-Meier analysis revealed a sig-
nificant recurrence-free survival (RFS) advantage with
p16 positivity across all treatment modalities (p=0.000)
(Figure 1). Further analysis demonstrated a significant in-
crease in RFS with p16-positivity when compared to other
biomarkers (p=0.029, Table 3) and when compared to
known prognosticators for recurrence (p=0.001, Table 4).
Table 2 Kaplan-Meier analysis of biomarker expression
and RFS in OPSCC patients from 2002–2009 for all
treatment modalities
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The typical staining pattern for Ki67 was predomin-
antly nuclear as expected. 56.5% of the tumour spec-
imens were found to be greater than the median
calculated for the cohort (975.67), and therefore,
Ki67-positive,. Chi-squared analysis revealed no significant
association between Ki67 expression and nodal dis-
ease at presentation (p=0.737) or distant metastasis
(p=0.189). Kaplan-Meier analysis demonstrated no
difference in RFS with elevated Ki67 staining
(p=0.319). No significant difference in RFS was noted
when compared to other biomarkers (p=0.108) or
when compared to known prognosticators for recur-
rence (p=0.165).Figure 1 Kaplan-Meier analysis of p16 expression and RFS in OPSCC fEFGR expression
High expression of EGFR was confirmed in 84.1% of pa-
tients. There was no association between high EGFR ex-
pression and nodal disease at presentation (p=0.427) or
development of distant metastatic disease (p=0.508).
Kaplan Meier analysis demonstrated no effect on RFS.
Cox regression analysis revealed no effect of high ex-
pression of EGFR on survival when compared to other
biomarkers (p=0.367) or known prognosticators for re-
currence (p=0.161).
p53 expression
High p53 expression was evident in 38.4% of tumour
specimens. There was no association between p53 ex-
pression and nodal disease at presentation (p=0.092)
or development of distant metastatic disease (0.561).
Kaplan-Meier analysis demonstrated significantly de-
creased RFS with high expression of p53 (p=0.005,
Table 2, Figure 2). Cox regression analysis revealed a sig-
nificantly decreased RFS when compared to other bio-
markers (p=0.021, Table 3), but the relationship became
non-significant when compared to known prognos-
ticators for recurrence and p16 expression (p=0.129,
Table 4).
Bcl-XL expression
High expression of Bcl-xL was demonstrated in 47.3% of
tumour specimens. High Bcl-xL expression was associatedrom 2002–2009 for all treatment modalities.
Figure 2 Kaplan-Meier analysis of p53 expression and RFS in OPSCC from 2002–2009 for all treatment modalities.
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not with development of distant metastases (p=0.852).
Combined biomarker analysis revealed a loose association
of Bcl-xL expression with p16 expression (p=0.086).
Kaplan-Meier analysis showed no effect on RFS. Cox re-
gression analysis demonstrated no significant effect on
RFS when compared to other biomarkers (p=0.231) or
known prognosticators for recurrence (p=0.111).
Discussion
There is significant variability and ambiguity in the
literature surrounding the role of biomarkers in
locoregional and distant metastasis. This is due, in part,
to a non-standardized methodology in the immunohisto-
chemical staining and quantification of biomarkers for
each tumour specimen and from each institution. For
example, immunohistochemical staining levels betweenTable 3 Cox regression analysis of biomarker expression
with RFS for all treatment modalities in OPSCC patients
from 2002–2009
Biomarker B CI P-value
p16 −0.891 0.215-0.782 0.029**
Ki67 0.178 0.569-2.514 0.108
Bcl-xL −0.312 0.392-1.369 0.231
EGFR 0.524 0.783-3.643 0.367
p53 0.330 1.033-3.765 0.021**
**Denotes statistical significance.slides within the same sample may have some variability
in staining intensity, and pathologists may be limited to
pseudo-quantitative methods in the interpretation of sig-
nal intensity. In addition, various antibodies have been
used by different research groups for different bio-
markers, with variable interpretations of signal positivity
that does not take into account differences in nuclear
versus cytoplasmic staining. Such biases may be over-
come using TMAs with standardized, automated and
quantitative immunohistochemical techniques, such as
AQUAnalysis®. The objectivity of the AQUAnalysis®
method allows for an unbiased assessment of biomarker
staining. Bose et al. [10] demonstrated superior metho-
dology in a study using AQUAnalysis® to correlate the
expression of Bax, Bcl-2, and Bcl-xL in oral cavity squa-
mous cell carcinoma specimens with disease-specific
survival, and demonstrated reliable and reproducible es-
timates of expression for each biomarker.Table 4 Cox regression analysis of biomarker levels with
RFS when compared to known prognosticators for
recurrence (stage, nodal status)
Biomarker B CI P-value
p16 −0.890 0.226-0.745 0.003**
p53 0.491 0.867-3.083 0.129
Stage 0.550 0.335-8.967 0.512
Nodal status 0.467 0.487-5.227 0.441
**Denotes statistical significance.
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demonstrated finding wherein p16 positivity can be
strongly correlated with a higher incidence of nodal disease
at presentation. Shonka Jr et al. [11] conducted a study in
69 OPSCC patients treated with primary radiotherapy,
with or without chemotherapy, and post-treatment neck
dissection. This study demonstrated that patients with
p16-positive tumours presented with more advanced loco-
regional disease - a finding consistent with the results of
our study. However, we have also demonstrated that nodal
disease at presentation can be correlated with high Bcl-xL
expression.
Bcl-xL is an anti-apoptotic protein in the Bcl-2 family
that has recently stimulated interest in the head and
neck cancer literature as a prognostic marker. However,
its specific role in lymph node metastases has not been
elucidated. Previous studies have demonstrated that high
Bcl-xL expression can be associated with chemoradiation
resistance [12,13]. A recent study demonstrated that
high Bcl-xL expression in conjunction with high p53 ex-
pression can produce Cisplatin resistance in vitro [14].
Furthermore, a study of 50 patients by Kumar et al.iii re-
vealed that high Bcl-xL expression alone was not associ-
ated with treatment response or survival outcomes, but
low expression levels in combination with low expres-
sion levels of p53 had higher overall and disease-specific
survival than alternative combinations, potentially supp-
orting the previous findings of chemoradiation resistance
in specimens with high levels of both Bcl-xL and p53.
No previous studies have examined the association of
Bcl-xL with locoregional metastases. Our study demon-
strates that high expression of Bcl-xL in OPSCC tumour
specimens is associated with positive nodal disease at
presentation. Although high expression of both p16 and
Bcl-xL was associated with nodal disease at presentation,
no correlation could be found between the biomarkers in
a combined analysis, suggesting a dichotomous pathway
for nodal spread wherein may Bcl-xL is associated
with the carcinogenically-mediated, and p53-associated,
OPSCC or an entirely different pathway of tumorigenesis
as opposed to the virally-mediated pathway involving p16
expression. Combined biomarker analysis did not demon-
strate a significant association between Bcl-xL and p53
expression in our study, suggesting that the latter explan-
ation may be the most accurate.
Our study showed that p53 was not correlated with
locoregional lymph node metastases or the development
of distant metastases. However, the consistency of asso-
ciation with higher recurrence rates with high p53 ex-
pression is appropriate in the context of a dichotomized
tumorigenesis pathway involving the distinction between
carcinogenically-mediated OPSCC and virally-mediated
OPSCC, wherein high expression of p53 is often
detected in carcinogenically-mediated, p16-negativetumors. Our demonstration of an inverse relationship in-
volving high p16 expression and low p53 expression in
combined biomarker analysis supports this dichotomy.
Increased incidence of p53 mutation in the setting of
continued carcinogenic insult supports a finding of in-
creased local recurrence as a result of adjacent and satel-
lite chromosomal aberration and cellular dysplasia.
Despite this, although studied extensively, p53 has not
demonstrated utility in predicting lymph node metasta-
ses in previous studies [15-19]. High levels, however,
have been shown to be associated with decreased overall
survival, likely as a result of recurrence as previously de-
scribed [20]. Again controversy exists regarding this
claim, as a systematic review by Tandon et al. [21] failed
to show any prognostic utility of p53 in predicting re-
sponse to treatment.
Similarly, despite extensive study, ambiguity surrounds
the role of EGFR in lymph node metastases. Due to the
intricate and extensive role of EGFR in signal transduc-
tion, aberrant EGFR function has potential to affect cell
cycle progression, apoptosis, and angiogenesis [22], and
high expression has been shown to be associated with
poor prognosis [23-25], yet this has been contended with
several opposing studies [26,27]. Despite high overall ex-
pression levels of EGFR positivity in our cohort, EGFR
was not shown to be predictive of nodal disease at pres-
entation or of development of distant metastatic disease.
Although high expression of EGFR is anticipated in
HNSCC, lack of literature consistency regarding its ef-
fect on metastasis and survival may be due to diverse
staining and isolation techniques, different quantitative
biomarker thresholds, or a lack of objective or auto-
mated biomarker quantification. In addition, as multiple
EGFR mutations exist, and multiple aberrations of the
downstream intracellular pathways exist, further study is
required to assess the optimal form, and dysfunction, to
measure regarding anomalies in the EGFR pathway.
Ki67 is a relatively novel biomarker of nuclear prolifer-
ation recently examined in the head and neck literature.
In a previous study by Boonkitticharoen et al. [28], man-
ual scoring technique was used to assess the degree of
positivity of oral and oropharyngeal SCC in association
with low expression of vascular endothelial growth fac-
tor (VEGF). This demonstrated that low VEGF and high
Ki67 levels were associated with lymph node metastases.
However, our study found no significant association with
nodal disease at presentation, the development of distant
metastases, or recurrence. Explanations for the discrep-
ancy in findings likely relate to diverse methods of im-
munostaining and immunohistochemical isolation
(particularly of concern given its ubiquitous existence in
the cell), differences in biomarker cutpoints, variation in
the density of Ki67 expression depending on the cellular
or tumor region examined (eg. nucleus or cytoplasm), or
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example, Klimowicz et al. [29] used AQUAnalysis® to
show that high basal Ki67 expression is associated with
improved prognosis in oral cavity SCC patients receiving
postoperative radiation therapy, whereas Nichols et al.
[30] demonstrated a higher rate of recurrence of early
glottic cancer with high Ki67 expression when treated
with radiotherapy.
There were several limitations in our study. This was a
retrospective study of a prospectively-collected database
of OPSCC patients from a single institution. Despite
sound quantitative analysis of biomarkers, a number of
samples were excluded due to an inadequate amount of
tumour tissue. This could be reduced with prospective
tumour banking and continued quantitative biomarker
analysis using AQUAnalysis.
The process of metastasis is complex. Factors that pro-
mote metastasis of cancer cells involve alterations in
genes and gene products at multiple stages in the cell
cycle and signal transduction pathways. Thus, in order
to determine utility in predicting locoregional or distant
metastases, multiple biomarkers must be evaluated, and
potential independent and combined function and dys-
function deciphered. Further study regarding the optimal
form of each biomarker to be measured, and the optimal
method of measurement of each biomarker should be
undertaken. Additionally, standardized and automated
quantitative immunohistochemistry should be utilized in
order to adequately compare findings between institu-
tions and ultimately, allow for individualization and
optimization of treatment by reducing toxicity.Conclusions
This study supports previous findings that high expres-
sion of p16 is associated with a higher incidence of nodal
disease at presentation, but a higher recurrence-free sur-
vival. However, this study has also demonstrated that
high Bcl-XL expression is associated with nodal disease
at presentation, but that none of the biomarkers can be
used as a reliable prognostic marker for distant metasta-
ses. Lastly we have demonstrated that an inverse rela-
tionship exists between p16 and p53 expression, that
high p53 expression may be useful as a prognostic factor
for recurrence in head and neck cancer, but that further
studies are necessary to assess the prognostic value of
biomarker profiling in OPSCC.
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